Well, with Pat Killingsworth campaigning to change multiple myeloma to bone marrow cancer, maybe on second thoughts I should change the title of the blog to Bone Marrow Cancer Overdrive.
Pat, I completely agree with you and support you. Myeloma can be quite a confusing name for a layperson. Bone marrow cancer is so much more self-explanatory.
That said; I have been busy with our Myeloma Cure Panel event that I had quite neglected the blog scene here at CureTalk. My apologies, and we are back to bringing you the latest, the best, and the most relevant.
To being with, here are three very interesting research articles on multiple myeloma.
- Possibly a new therapeutic target may have been identified for Myeloma. In two large cohorts of untreated patients, myeloma cells were seen to exhibit significantly increased levels of bone-remodeling protein annexin A2 (ANXA2), which lead to inferior event-free and overall survival in study population of both cohorts. The study has been published in the journal Blood.
- Results of Senesco Technologies Inc.’s non-clinical study of SNSo1-T in combination with lenalidomide was announced in the beginning of the week. The results show that combination of SNCo1-T and lenalidomide (REVLIMID) is far more effective in inhibiting tumor growth in multiple myeloma than when either of the drugs was administered alone.
- Scientists at Virginia Commonwealth University Massey Cancer Center have found out in pre-clinical studies (non-human) that a combination of obatoclax and flavopiridol caused multiple myeloma cell death. The study results have been published in the journal Cancer Research. The drug combination worked by inducing apoptosis or cell suicide among myeloma cells.
Quite a few research studies on myeloma, I should say! The amount of research being conducted to find a way to fight myeloma is a clear indication of the active recognition of the need of the hour for myeloma patients. Myeloma is the second most common form of blood cancer and as of now, there is no complete cure for the condition.
However, all the research that is going on provides ample hope to myeloma survivors everywhere.
- Interleukin-16 in Multiple Myeloma: New Diagnostic/Prognostic Treatment?
- 5 Multiple Myeloma Clinical Trials Currently Recruiting
- Lenalidomide (Revlimid) For Maintenance Therapy Post Stem Cell Tranplantation In Multiple Myeloma: Two Studies
- What is Multiple Myeloma, what causes Multiple Myeloma and where to look for Multiple Myeloma clinical trials
- Multiple Myeloma Research Consortium (MMRC) Opens Record-Breaking Number of Trials in 2011 to Advance Multiple Myeloma Treatments